Postępy Psychiatrii i Neurologii
2/2026 vol. 35
Artykuł oryginalny

Diagnostic utility of Addenbrooke’s Cognitive Examination III in differentiating Alzheimer’s disease dementia, vascular dementia, and mixed dementia

Anna Barczak 1
  1. Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
Adv Psychiatry Neurol 2026; 35 (2): 85-93
DOI: https://doi.org/10.5114/ppn.2026.161371
Data publikacji online: 2026/05/13
Plik artykułu
PPiN-00578-Diagnostic.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Jørgensen IF, Aguayo-Orozco A, Lademann M, Brunak S. Age-stratified longitudinal study of Alzheimer’s and vascular dementia patients. Alzheimers Dement 2020; 16: 908-917.
  2. Custodio N, Montesinos R, Lira D, Herrera-Pérez E, Bardales Y, Valeriano-Lorenzo L. Mixed dementia: a review of the evidence. Dement Neuropsychol 2017; 11: 364-370.
  3. Burgueño-García I, López-Martínez MJ, Uceda-Heras A, García-Carracedo L, Zea-Sevilla MA, Rodrigo-Lara H, et al. Neuropathological heterogeneity of dementia due to combined pathology in aged patients: clinicopathological findings in the Vallecas Alzheimer’s Reina Sofía Cohort. J Clin Med 2024; 13: 6755. DOI: 10.3390/jcm13226755.
  4. Chang Wong E, Chang Chui H. Vascular cognitive impairment and dementia. Continuum (Minneap Minn) 2022; 28: 750-780.
  5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-269.
  6. Sokolovič L, Hofmann MJ, Mohammad N, Kukolja J. Neuropsychological differential diagnosis of Alzheimer’s disease and vascular dementia: a systematic review with meta-regressions. Front Aging Neurosci 2023; 15: 1267434. DOI: 10.3389/fnagi.2023.1267434.
  7. Ng S, Hornblass A, Habibi P, Ikramuddin S, Chen J, Feng W, Cai D. Updates on vascular dementia. Stroke Vasc Neurol 2025. DOI: 10.1136/svn-2025-004048.
  8. Macoir J. Language impairment in vascular dementia: a clinical review. J Geriatr Psychiatry Neurol 2024; 37: 87-95.
  9. Maciel DG, Golden CJ. Review of the efficacy of methods in the early detection of vascular dementia. Arch Assess Psychol 2022; 12: 3. Available at: https://nsuworks.nova.edu/psyassessment/vol12/iss1/3.
  10. Chui HC, Ramirez-Gomez L. Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther 2015; 7: 21. DOI: 10.1186/s13195-015-0104-7.
  11. Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 2017; 13: 457-476.
  12. Barczak A. What should a neurologist know about a neuropsychological examination? Aktualn Neurol 2024; 24: 77-83 [In Polish].
  13. Tomaszewska M, Chibowska P, Sitek EJ. Selected cognitive screening tests in different clinical settings. Psychiatr Psychol Klin 2021; 21: 257-267 [In Polish].
  14. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord 2013; 36: 242-250.
  15. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699. Erratum in: J Am Geriatr Soc 2019; 67: 1991. DOI: 10.1111/jgs.15925.
  16. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
  17. Yamamoto E, Mourany L, Colleran R, Whitman C, Tousi B. Utility of Montreal Cognitive Assessment in differentiating dementia with Lewy bodies from Alzheimer’s dementia. Am J Alzheimers Dis Other Demen 2017; 32: 468-471.
  18. Wood JL, Weintraub S, Coventry C, Xu J, Zhang H, Rogalski E, et al. Montreal Cognitive Assessment (MoCA) performance and Domain-Specific Index Scores in amnestic versus aphasic dementia. J Int Neuropsychol Soc 2020; 26: 927-931.
  19. Coleman KK, Coleman BL, MacKinley JD, Pasternak SH, Finger EC. Association between Montreal Cognitive Assessment sub-item scores and Corresponding Cognitive Test performance in patients with frontotemporal dementia and related disorders. Dement Geriatr Cogn Disord 2017; 43: 170-179.
  20. Afrashteh F, Almasi-Dooghaee M, Kamyari N, Rajabi R, Baradaran HR. Is Montreal Cognitive Assessment a valuable test for the differentiation of Alzheimer’s disease, frontotemporal dementia, dementia with Lewy body, and vascular dementia? Dement Neuropsychol 2024; 18: e20230124. DOI: 10.1590/1980-5764-DN-2023-0124.
  21. Carrick J, Cheung SC, Foxe D, Piguet O. Interpreting Addenbrooke’s Cognitive Examination-III scores in dementia: performance distributions and clinically meaningful change. Eur J Neurol 2025; 32: e70257. DOI: 10.1111/ene.70257.
  22. Sitek EJ, Barczak A, Senderecka M. A qualitative analysis of the ACE-III profile in the differential diagnosis of dementia syndromes. Aktualn Neurol 2017; 17: 34-41.
  23. Matías-Guiu JA, Valles-Salgado M, Rognoni T, Hamre-Gil F, Moreno-Ramos T, Matías-Guiu J. Comparative diagnostic accuracy of the ACE-III, MIS, MMSE, MoCA, and RUDAS for screening of Alzheimer disease. Dement Geriatr Cogn Disord 2017; 43: 237-246.
  24. Potts C, Richardson J, Bond RB, Price RK, Mulvenna MD, Zvolsky P, et al. Reliability of Addenbrooke’s Cogni­tive Examination III in differentiating between dementia, mild cognitive impairment and older adults who have not reported cognitive problems. Eur J Ageing 2021; 19: 495-507.
  25. Rezaei S, Asgari Mobarake K, Jafroudi M, Saberi A, Hosseininezhad M, Bakhshayesh Eghbali B, et al. Validation of the Addenbrooke’s Cognitive Examination-III for detecting vascular dementia in Iranian patients with stroke: a secondary data analysis. Appl Neuropsychol Adult 2024. DOI: 10.1080/23279095.2024.2429549.
  26. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672-2713.
  27. Gabryelewicz T, Styczynska M, Luczywek E, Barczak A, Pfeffer A, Androsiuk W, et al. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry 2007; 22: 563-567.
  28. JASP Team. JASP (Version 0.19.5) [Computer software]. Amsterdam: University of Amsterdam; 2025. Available from: https://jasp-stats.org.
  29. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York: Lawrence Erlbaum Associates; 1988.
  30. Kalaria RN. The pathology and pathophysiology of vascular dementia. Neuropharmacology 2018; 134(Pt B): 226-239.
  31. Valdez-Gaxiola CA, Rosales-Leycegui F, Gaxiola-Rubio A, Moreno-Ortiz JM, Figuera LE. Early- and late-onset Alzheimer’s disease: two sides of the same coin? Diseases 2024; 12: 110. DOI: 10.3390/diseases12060110.
  32. Raimondi C, Gleichgerrcht E, Richly P, Torralva T, Roca M, Camino J, et al. The Spanish version of the Addenbrooke’s Cognitive Examination – Revised (ACE-R) in subcortical ischemic vascular dementia. J Neurol Sci 2012; 322: 228-231.
  33. Kaczmarek B, Ilkowska Z, Kropinska S, Tobis S, Krzyminska-Siemaszko R, Kaluzniak-Szymanowska A, et al. Applying ACE-III, M-ACE and MMSE to diagnostic screening assessment of cognitive functions within the Polish population. Int J Environ Res Public Health 2022; 19: 12257. DOI: 10.3390/ijerph191912257.
  34. McCarthy L, Rubinsztein J, Lowry E, Flanagan E, Menon V, Vearncombe S, et al. Cut-off scores for mild and moderate dementia on the Addenbrooke’s Cognitive Examination-III and the Mini-Addenbrooke’s Cognitive Examination compared with the Mini-Mental State Examination. BJPsych Bull 2024; 48: 12-18.
  35. Piccininni M, Rohmann JL, Wechsung M, Logroscino G, Kurth T. Should Cognitive Screening Tests be corrected for age and education? Insights from a causal perspective. Am J Epidemiol 2023; 192: 93-101.
  36. Cavanagh L, Paulsen JS. Neuropsychology and vascular cognitive impairment and dementia. Neurol Clin 2024; 42: 809-820.
  37. Vollhardt A, Frölich L, Stockbauer AC, Danek A, Schmitz C, Wahl AS. Towards a better diagnosis and treatment of dementia: identifying common and distinct neuropathological mechanisms in Alzheimer’s and vascular dementia. Neurobiol Dis 2025; 208: 106845. DOI: 10.1016/j.nbd.2025.106845.
  38. Budson AE. Understanding memory dysfunction. Neurologist 2009; 15: 71-79.
  39. Herbert V, Brookes RL, Markus HS, Morris RG. Verbal fluency in cerebral small vessel disease and Alzheimer’s disease. J Int Neuropsychol Soc 2014; 20: 413-421.
  40. Eckerström C, Eckerström M, Göthlin M, Molinder A, Jonsson M, Kettunen P, et al. Characteristic biomarker and cognitive profile in incipient mixed dementia. J Alzheimers Dis 2020; 73: 597-607.
  41. Pal A, Biswas A, Pandit A, Roy A, Guin D, Gangopadhyay G, et al. Study of visuospatial skill in patients with dementia. Ann Indian Acad Neurol 2016; 19: 83-88.
  42. Heinik J, Solomesh I, Raikher B, Lin R. Can clock drawing test help to differentiate between dementia of the Alz­heimer’s type and vascular dementia? A preliminary study. Int J Geriatr Psychiatry 2002; 17: 699-703.
  43. Tan LP, Herrmann N, Mainland BJ, Shulman K. Can clock drawing differentiate Alzheimer’s disease from other dementias? Int Psychogeriatr 2015; 27: 1649-1660.
  44. Torisson G, van Westen D, Stavenow L, Minthon L, Londos E. Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients. BMC Geriatr 2015; 15: 65. DOI: 10.1186/s12877-015-0066-4.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). License allowing third parties to download and share its works but not commercially purposes or to create derivative works.
Udostępnij
without publication fees
Dostępne w
Indeksowane w
pubmed
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications